Pharmaceutical giant Elan today reported a 17% revenue increase resulting in a net loss from continuing operations of $31.8m (€24.08m) in its first-quarter 2012 financial results. The figure includes a loss of $13.3m (€10m) from the disposal of 76% of the company’s shareholding in Alkermes plc in March 2012. The net loss from continuing operations for the same period of 2011 was $27.7m (€20.9m). Total revenue for the first quarter of 2012 increased to $288.4m (€218.4m) from $247.1m (€187.1m) for the same period of 2011, as a result of the 14% growth in global in-market net sales of Tysabri to $399m (€302.1m) for the first quarter of 2012, from $349.4m (€264.6m) for the same period of 2011.
